BR112023024550A2 - Novos sais de n,n-dimetiltriptamina e formas de sal cristalino - Google Patents

Novos sais de n,n-dimetiltriptamina e formas de sal cristalino

Info

Publication number
BR112023024550A2
BR112023024550A2 BR112023024550A BR112023024550A BR112023024550A2 BR 112023024550 A2 BR112023024550 A2 BR 112023024550A2 BR 112023024550 A BR112023024550 A BR 112023024550A BR 112023024550 A BR112023024550 A BR 112023024550A BR 112023024550 A2 BR112023024550 A2 BR 112023024550A2
Authority
BR
Brazil
Prior art keywords
salts
salt forms
crystalline salt
new
dimethyltriptamine
Prior art date
Application number
BR112023024550A
Other languages
English (en)
Inventor
Fawaz Majed
KASERA Setu
Morra Nicholas
Original Assignee
Atai Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Atai Therapeutics Inc filed Critical Atai Therapeutics Inc
Publication of BR112023024550A2 publication Critical patent/BR112023024550A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/14—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
    • C07D209/16—Tryptamines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C55/00—Saturated compounds having more than one carboxyl group bound to acyclic carbon atoms
    • C07C55/02—Dicarboxylic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C55/00—Saturated compounds having more than one carboxyl group bound to acyclic carbon atoms
    • C07C55/02—Dicarboxylic acids
    • C07C55/06—Oxalic acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C55/00—Saturated compounds having more than one carboxyl group bound to acyclic carbon atoms
    • C07C55/02—Dicarboxylic acids
    • C07C55/08—Malonic acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C55/00—Saturated compounds having more than one carboxyl group bound to acyclic carbon atoms
    • C07C55/02—Dicarboxylic acids
    • C07C55/10—Succinic acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C57/00—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
    • C07C57/02—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms with only carbon-to-carbon double bonds as unsaturation
    • C07C57/13—Dicarboxylic acids
    • C07C57/15—Fumaric acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Photoreceptors In Electrophotography (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicinal Preparation (AREA)

Abstract

novos sais de n,n-dimetiltriptamina e formas de sal cristalino. esta divulgação fornece sais de n,n-dimetiltriptamina e formas cristalinas de sal, sua preparação, composições farmacêuticas compreendendo os referidos sais e formas cristalinas de sal e sua utilização no tratamento de doenças e condições neurológicas.
BR112023024550A 2021-05-25 2022-05-25 Novos sais de n,n-dimetiltriptamina e formas de sal cristalino BR112023024550A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202163192938P 2021-05-25 2021-05-25
PCT/US2022/030912 WO2022251351A1 (en) 2021-05-25 2022-05-25 New n,n-dimethyltryptamine salts and crystalline salt forms

Publications (1)

Publication Number Publication Date
BR112023024550A2 true BR112023024550A2 (pt) 2024-02-06

Family

ID=84230260

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112023024550A BR112023024550A2 (pt) 2021-05-25 2022-05-25 Novos sais de n,n-dimetiltriptamina e formas de sal cristalino

Country Status (12)

Country Link
US (1) US20220388956A1 (pt)
EP (1) EP4347562A1 (pt)
JP (1) JP2024521747A (pt)
KR (1) KR20240013170A (pt)
CN (1) CN117545739A (pt)
AU (1) AU2022281358A1 (pt)
BR (1) BR112023024550A2 (pt)
CA (1) CA3218110A1 (pt)
CL (1) CL2023003518A1 (pt)
IL (1) IL308816A (pt)
MX (1) MX2023013928A (pt)
WO (1) WO2022251351A1 (pt)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3219041A1 (en) * 2021-05-24 2022-12-01 Canna-Chemistries Llc Crystalline salts of psilocin
CA3238440A1 (en) 2021-12-30 2023-07-06 Atai Therapeutics, Inc. Dimethyltryptamine analogues as nitric oxide delivery drugs
WO2024023274A2 (en) * 2022-07-27 2024-02-01 Reconnect Labs Ag Highly soluble formulations of harmine

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050245594A1 (en) * 2001-06-29 2005-11-03 Sutter Diane E Dermal delivery of anti-pain agents and methods useful thereof
US20090093513A1 (en) * 2007-10-09 2009-04-09 Hamann Mark T Method to Use Compositions Having Antidepressant Anxiolytic and Other Neurological Activity and Compositions of Matter
WO2010151258A1 (en) * 2009-06-24 2010-12-29 The Board Of Regents Of The University Of Oklahoma Methods of treating psychological conditions
DK2828385T3 (en) * 2012-03-23 2018-03-12 Codexis Inc BIOCATALIZATORS AND METHODS FOR SYNTHETIZING DERIVATIVES AND TRYPTAMIN AND TRYPTAMINE ANALOGS

Also Published As

Publication number Publication date
EP4347562A1 (en) 2024-04-10
KR20240013170A (ko) 2024-01-30
IL308816A (en) 2024-01-01
CL2023003518A1 (es) 2024-05-03
CA3218110A1 (en) 2022-12-01
WO2022251351A4 (en) 2022-12-29
JP2024521747A (ja) 2024-06-04
AU2022281358A1 (en) 2023-11-23
US20220388956A1 (en) 2022-12-08
MX2023013928A (es) 2023-12-08
WO2022251351A1 (en) 2022-12-01
CN117545739A (zh) 2024-02-09

Similar Documents

Publication Publication Date Title
BR112023024550A2 (pt) Novos sais de n,n-dimetiltriptamina e formas de sal cristalino
UY38425A (es) Procesos novedosos para preparar n-((1,2,3,5,6,7-hexahidro-s-indacen-4-il)carbamoil)-1- isopropil-1h-pirazol-3-sulfonamida y sales de éste
UY38186A (es) Sal sódica de n-((1,2,3,5,6,7-hexahidro-s-indacen-4-il)carbamoil)-1-isopropil-1h-pirazol-3-sulfonamida
BR112019007393A2 (pt) derivados 6,7,8,9-tetra-hidro-3h-pirazolo[4,3-f]isoquinolina úteis no tratamento de câncer
TR201901312T4 (tr) Mcl-1 proteinini inhibe eden tetrahidronaftalen türevleri.
BR112015029512A8 (pt) derivados de pirazolopirrolidina, seus usos, e composição e combinação farmacêuticas
BR112018070304A2 (pt) formulações líquidas de (s)-n-(5-((r)-2-(2,5-difluorofenil)-pirrolidin-1-il)-pirazolo[1,5-a]pirimidin-3-il)-3-hidroxipirrolidina-1-carboxamida
BR112017002403A2 (pt) formas de cristais de inibidores de glutaminase
CL2020002512A1 (es) Tratamiento de la hidradenitis supurativa mediante el uso de inhibidores de jak.
EA202191239A1 (ru) Соединения и их применение для лечения дефицита 1-антитрипсина
BR112015029401A8 (pt) derivados de pirazolo-pirrolidin-4-ona, seus usos, e composição e combinação farmacêuticas
BR112021008873A8 (pt) Formulação
BR112019002730A2 (pt) acetil-leucina, ou um sal farmaceuticamente aceitável da mesma, para uso em um método de tratamento de uma doença neurodegenetativa
ECSP22038978A (es) INHIBICIÓN DE INTEGRINA ALFA4ß7 HUMANA
AR117614A1 (es) Forma de dosificación farmacéutica administrable por vía oral con liberación modificada
BR112016029067A2 (pt) ?composto, composição farmacêutica, e, métodos para inibir o canal de potássio medular externo renal, para causar diurese, natriurese ou ambas e para tratar um ou mais distúrbios?
UY38228A (es) Compuestos de triazolopirimidina y su uso en el tratamiento del cáncer
EA201892265A1 (ru) Способы лечения офтальмологических заболеваний
CO2021000450A2 (es) Forma de dosificación farmacéutica administrable por vía oral con liberación modificada
PE20180039A1 (es) Piroglutamato de vortioxetina
CO2020016480A2 (es) Sales tópicas de amlodipino para el tratamiento de enfermedades anorrectales
BR112017001160A2 (pt) [1,2,4]triazol[4,3-b]piridazinas para uso no tratamento de doenças proliferativas
BR112022003719A2 (pt) Métodos para o tratamento de hiperfenilalaninemia
AR103118A1 (es) Tratamientos médicos basados en anamorelina
BR112017025668A2 (pt) derivados de imidazo [1,2-b] [1,2,4] triazina como agentes antiparasitários